Clinical Trials Logo

Dyslipidemias clinical trials

View clinical trials related to Dyslipidemias.

Filter by:

NCT ID: NCT00547274 Terminated - Dyslipidemia Clinical Trials

Dyslipidemia in Type 2 Diabetes (0767-034)

Start date: July 2003
Phase: Phase 3
Study type: Interventional

The purpose of the study is to compare the lipid-altering effects of MK0767, glipizide, and pioglitazone after 12 weeks of treatment. This is an early phase trial and some specific protocol information is in progress and not publicly available at this time. (Full information is available to trial participants).

NCT ID: NCT00477477 Terminated - Hypertension Clinical Trials

Nutritional Treatment of Overweight Adolescents With Cardiovascular Risk Factors (PowerUp)

Start date: May 2007
Phase: N/A
Study type: Interventional

This study is designed to evaluate the efficacy of two diets, a low glycemic load diet and a low saturated fat diet, in the treatment of adolescents with some heart disease risk factors associated with being overweight, such as high blood pressure, pre-diabetes, and cholesterol problems. The objective of the study is to determine which diet improves these risk factors more. The design of the study is a modified feeding study, which requests that the participants eat all and only the food provided by the study for 8 weeks, most days per week. Dietary counseling by phone will continue between 2 and 6 months of the study and the effects of this maintenance period will be assessed at 6 months time.

NCT ID: NCT00458081 Terminated - Obesity Clinical Trials

Evaluation of the Rimonabant Impact on the Regression of Asymptomatic Damage Caused by Cardiovascular Risk Factors

RIALTO
Start date: March 2007
Phase: Phase 3
Study type: Interventional

Primary objective: - To assess the effect on microalbuminuria levels of treatment with rimonabant 20 mg versus a placebo during a 12 month period. Secondary objectives: - Percentage of patients in both arms of the study whose levels of microalbuminuria decrease, stabilise, increase towards macroalbuminuria or are unchanged after 12 months of treatment with rimonabant or placebo. - To assess the effect of treatment with rimonabant 20 mg versus placebo over a 12 month period on: - Weight and waist circumference. - Glycaemia profile: fasting glycaemia, fasting insulinaemia and HbA1c. - Lipid and lipoprotein profile: triglycerides, total cholesterol, HDL-C, LDL-C, apolipoproteins A1 and B. - Inflammatory markers - Adipocytokines. - Blood pressure. - Glomerular filtration rate. - To assess the quality of life by means of questionnaire filled in. - Safety parameters

NCT ID: NCT00434096 Terminated - Obesity Clinical Trials

Japanese Study of Rimonabant in Obese Patients With Dyslipidemia (VENUS)

Start date: February 2007
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to assess the efficacy of SR141716 compared to placebo on body weight and triglycerides changes over a period of 52 weeks. Secondary objectives are: - To evaluate the effect of SR141716 compared to placebo over a period of 52 weeks, on HDL-cholesterol and visceral fat area. - To evaluate the safety of SR141716 compared to placebo over a period of 104 weeks. - To evaluate the pharmacokinetics of SR141716.

NCT ID: NCT00412698 Terminated - Obesity Clinical Trials

European Trial About Effect of RimoNabant on Abdominal Obese Patients With dysLipidemia

ETERNAL
Start date: December 2006
Phase: Phase 3
Study type: Interventional

Primary : To determine the effect of Rimonabant 20 mg on changes in, HDL-Cholesterol (HDL-C), triglyceride levels over a period of 12 months when prescribed with a mild hypocaloric diet in abdominally obese patients with dyslipidemia with or without other associated comorbidities. Main Secondary : To determine the effect of 12 months Rimonabant treatment versus placebo on changes in waist circumference (WC), body weight, glycemic and lipid parameters. To assess the safety of 12 months Rimonabant treatment versus placebo in these patients. In selected sites, a sub study will be conducted to determine the effect of 12 months of Rimonabant on additional lipoprotein and inflammatory parameters.

NCT ID: NCT00362765 Terminated - Type 2 Diabetes Clinical Trials

Fenofibrate and Metformin Insulin Sensitivity in Type 2 Diabetics Study

Start date: October 2006
Phase: Phase 2/Phase 3
Study type: Interventional

Double-blind, randomized placebo-controlled study in type 2 diabetes and dyslipidemic patients.Patients will be randomized to one of four treatment arms for 16 weeks: placebo, fenofibrate, metformin, or metformin and fenofibrate combination.

NCT ID: NCT00361868 Terminated - Dyslipidemia Clinical Trials

Fenofibrate and Metformin Fixed Combination vs Rosiglitazone - FAME ROSI

Start date: June 2006
Phase: Phase 3
Study type: Interventional

Under conditions of first-line drug treatment in antidiabetic drug naïve/drug free patients with type 2 diabetes mellitus and dyslipidemia, to show that :- the efficacy of a fixed combination (FC) of fenofibrate and metformin on glycemic control is not inferior to that of rosiglitazone and the efficacy of FC of fenofibrate and metformin on triglyceride control is superior to that of rosiglitazone.

NCT ID: NCT00337415 Terminated - Dyslipidemia Clinical Trials

MK0354 Clinical Efficacy and Tolerability Study (0354-004)

Start date: May 2006
Phase: Phase 2
Study type: Interventional

A Research Study to Evaluate the Effectiveness and Tolerability of MK0354 vs Placebo (an inactive look alike pill) in Lipid (fat) Altering in Patients with dyslipidemia (a disorder of lipids in the blood) This is an early phase trial and some specific protocol information is proprietary and not publicly available at this time. (Full information is available to trial participants).

NCT ID: NCT00318617 Terminated - Heart Failure Clinical Trials

Effect Of GW501516X On How The Heart Obtains And Uses Energy

Start date: December 2005
Phase: N/A
Study type: Observational

The purpose of this study is to determine the effect of a 4-week treatment period with GW501516X on how the heart obtains and uses energy. The energy of the heart will be measured by Magnetic Resonance Imaging (MRI). This study will also measure a number of other potential markers of drug activity, including levels of certain lipids (fats) and proteins in your blood. The data from this study may help researchers better understand the actions of this drug in the body and if this drug may be useful to treat patients with heart disease.

NCT ID: NCT00267280 Terminated - Clinical trials for Hypercholesterolemia

A Clinical Trial Comparing Torcetrapib/Atorvastatin To Simvastatin In Subjects With High Cholesterol (A5091031).

Start date: January 2006
Phase: Phase 3
Study type: Interventional

The Torcetrapib project was terminated on December 2, 2006 due to safety findings. Cholesterol levels will be measured over six weeks in subjects being treated with two different kinds of cholesterol medications to see how the different treatments compare to one another.